Website Video

Partner of choice in specialty, hospital, and rare disease medicines

Learn More

ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the medicines they depend on.

Our ambition is to be the partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients worldwide.

Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20, including key countries in Europe, Canada, and Australia. Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations.

For decades, ADVANZ PHARMA has been committed to providing patients with a wide range of high quality and trusted specialty medicines. We cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases.

Leveraging generations of knowledge and expertise, ADVANZ PHARMA is rapidly building a diverse, long-term portfolio of biosimilars, underscoring our commitment to expanding treatment options - both now and in the future - aimed at enhancing patient care, lowering costs, and addressing the changing needs of healthcare systems.

We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Discover who we are

Latest News —

Image for ADVANZ PHARMA Acquires Territory Rights to Progynova® and Cyclo-Progynova® in Selected Countries in EMEA and Global Rights to Ilomedin®

Press Releases — 18 Dec 2025

ADVANZ PHARMA Acquires Territory Rights to Progynova® and Cyclo-Progynova® in Selected Countries in EMEA and Global Rights to Ilomedin®

Learn more
Image for Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz® a Biosimilar to Simponi® (golimumab)

Press Releases — 20 Nov 2025

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz® a Biosimilar to Simponi® (golimumab)

Learn more
Image for Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Press Releases — 06 Nov 2025

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Learn more
Image for ADVANZ PHARMA Acquires Global Rights to Rare Disease Specialty Brand Zavesca®

Press Releases — 13 Oct 2025

ADVANZ PHARMA Acquires Global Rights to Rare Disease Specialty Brand Zavesca®

Learn more
Image for European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Press Releases — 06 Oct 2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Learn more
Image for European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Press Releases — 22 Sep 2025

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Learn more

Our portfolio —

ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands

Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare diseases.

Careers & Culture —

The success of any company is driven by its people, and we are no different. We aim to be the best team in the industry by embracing challenges and change. We live our company values Entrepreneurship, Speed, and Integrity.

Our Partnerships —

Partnerships are a fundamental part of our business.. We work with >300 partners in production, development, portfolio licensing, and commercialization. We cooperate very closely with them and invest significantly to help broaden patient access and to improve health outcomes.

Subscribe for the latest press releases delivered to your inbox

Please select all the ways you would like to hear from ADVANZ PHARMA:

You can unsubscribe at any time by clicking the link in the footer of our emails.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.